Adicet Bio, Inc. (ACET) Stock Price & Analysis
Adicet Bio, Inc. (ACET) closed at USD 5.14 on Thursday, October 15, 2026, up 5.11% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.89; the Oct 15, 2026 session ranged USD 4.88–5.17 on volume of 155,089 shares. Market capitalization is $48.12M, with a 52-week range of USD 4.8–16.96 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACET.md
Key facts (ACET)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 34.83 (range 18–90).
- Total return with dividends: 1Y -69.1% vs S&P 500 +18.1%; 5Y -96.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.58, revenue estimate $0K.
Analysts (ACET)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 34.83 (low 18, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Wedbush | Target raised | Outperform | $25 → $28 |
| 2026-09-28 | HC Wainwright & Co. | Target raised | Buy | $27 → $34 |
| 2026-09-18 | HC Wainwright & Co. | Reiterated | Buy | $27 |
| 2026-08-06 | Guggenheim | Target lowered | Buy | $100 → $90 |
Total return (dividends reinvested) (ACET)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -69.1% | -96.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -69.2% | -47.4% |
| Volatility (annualized) | 78.4% | 90.1% |
| Max drawdown | -70.6% (Oct 2025→Oct 2026) | -98.5% (Nov 2022→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 5.14 |
|---|---|
| Change | ▲ 5.11% (up) |
| Previous Close | USD 4.89 |
| Open | USD 4.9 |
| Day Range | USD 4.88 – 5.17 |
| 52-Week Range | USD 4.8 – 16.96 |
| Volume | 155,089 shares |
| Market Cap | $48.12M |
| Exchange | NCM |
Technical Analysis (ACET)
Nexqual's technical model rates ACET "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.32 (oversold) |
| vs SMA50 | Below (USD 8.12) |
| MACD | -0.96 (negative) |
Analyst Ratings (ACET)
Wall Street analysts rate ACET "Buy" based on 6 analysts, with a mean price target of USD 34.83 (range USD 18–90), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 34.83 |
| High Target | USD 90 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ACET)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.58 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.99 vs est -1.64 ▼ miss |
| 2026-03-31 | USD -1.88 vs est -3.08 ▲ beat |
| 2025-12-31 | USD -2.94 vs est -2.99 ▲ beat |
| 2025-09-30 | USD -4.64 vs est -5.07 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (ACET)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -78.08% |
| Debt / Equity | 0.11 |
| Current Ratio | 6.71 |
| Total Cash | $118.19M |
| Total Debt | $12.85M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (ACET)
Nexqual rates Adicet Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $118M cash vs $13M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$85M (TTM) |
| Efficiency | Critical — ROE -78%, ROA -41.7% |
Ownership (ACET)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +64.72% |
| Shares Outstanding | 9.36M |
| Float | 7.43M |
| Short % of Float | +5.20% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (ACET)
Adicet Bio, Inc. is led by Chen Schor BA (age 53), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Director | Chen Schor BA (age 53) |
|---|---|
| Senior VP & Chief Scientific Officer | Blake Aftab (age 44) |
| Interim Chief Medical Officer & Director | Lloyd Klickstein (age 68) |
| Chief Financial Officer | Brian Nicholas Harvey (age 64) |
| Chief Technology Officer | Donald Healey (age 63) |
Major Backers & Investors (ACET)
Notable institutional backers of Adicet Bio, Inc. include RA Capital Management, L.P., Orbimed Advisors LLC., Franklin Resources, Inc., according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.96% |
| Orbimed Advisors LLC. | 9.02% |
| Franklin Resources, Inc. | 6.69% |
| Citadel | 4.62% |
| Adage Capital Partners GP L.L.C. | 2.93% |
| Renaissance Technologies | 2.84% |
| Stonepine Capital Management, LLC | 2.62% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 2.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.3% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt